Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 76 | 2021 | 438 | 11.310 |
Why?
|
| Anti-Asthmatic Agents | 12 | 2020 | 72 | 2.930 |
Why?
|
| Adrenal Cortex Hormones | 14 | 2021 | 163 | 2.220 |
Why?
|
| Severity of Illness Index | 28 | 2021 | 926 | 2.110 |
Why?
|
| Phenotype | 24 | 2021 | 656 | 2.060 |
Why?
|
| Sputum | 9 | 2021 | 43 | 1.510 |
Why?
|
| Bronchodilator Agents | 12 | 2021 | 89 | 1.370 |
Why?
|
| Lung | 12 | 2021 | 262 | 1.290 |
Why?
|
| Bronchoscopy | 4 | 2019 | 57 | 1.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2021 | 142 | 1.130 |
Why?
|
| Eosinophils | 10 | 2021 | 55 | 1.080 |
Why?
|
| Forced Expiratory Volume | 19 | 2020 | 126 | 0.970 |
Why?
|
| Adult | 50 | 2021 | 9467 | 0.900 |
Why?
|
| Cluster Analysis | 6 | 2019 | 131 | 0.880 |
Why?
|
| Humans | 79 | 2021 | 32292 | 0.870 |
Why?
|
| Neutrophils | 5 | 2020 | 118 | 0.860 |
Why?
|
| Adolescent | 29 | 2020 | 3571 | 0.800 |
Why?
|
| Respiratory Function Tests | 14 | 2021 | 122 | 0.770 |
Why?
|
| Male | 56 | 2021 | 19487 | 0.770 |
Why?
|
| Female | 56 | 2021 | 20125 | 0.760 |
Why?
|
| Dyspnea | 2 | 2019 | 34 | 0.720 |
Why?
|
| Cough | 1 | 2019 | 20 | 0.680 |
Why?
|
| Middle Aged | 38 | 2021 | 11949 | 0.660 |
Why?
|
| Biological Products | 1 | 2020 | 78 | 0.650 |
Why?
|
| Bronchi | 7 | 2021 | 45 | 0.640 |
Why?
|
| Young Adult | 19 | 2020 | 2626 | 0.640 |
Why?
|
| Leukocyte Count | 5 | 2020 | 64 | 0.620 |
Why?
|
| Hypersensitivity | 2 | 2017 | 27 | 0.600 |
Why?
|
| Albuterol | 6 | 2019 | 40 | 0.590 |
Why?
|
| Glucocorticoids | 5 | 2020 | 161 | 0.590 |
Why?
|
| Immunologic Factors | 1 | 2017 | 49 | 0.580 |
Why?
|
| Immunotherapy | 1 | 2017 | 83 | 0.570 |
Why?
|
| Smoking | 2 | 2021 | 493 | 0.550 |
Why?
|
| Child | 22 | 2019 | 2472 | 0.550 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2020 | 77 | 0.530 |
Why?
|
| Administration, Inhalation | 11 | 2019 | 94 | 0.520 |
Why?
|
| Immunoglobulin E | 8 | 2020 | 50 | 0.500 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2020 | 1092 | 0.490 |
Why?
|
| Cohort Studies | 13 | 2021 | 1832 | 0.460 |
Why?
|
| Receptors, Adrenergic, beta-2 | 4 | 2019 | 36 | 0.430 |
Why?
|
| Granulocytes | 3 | 2021 | 17 | 0.400 |
Why?
|
| Aged | 19 | 2021 | 10398 | 0.400 |
Why?
|
| European Continental Ancestry Group | 9 | 2019 | 1180 | 0.370 |
Why?
|
| Nitric Oxide | 7 | 2019 | 121 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 410 | 0.340 |
Why?
|
| Alendronate | 2 | 2019 | 12 | 0.340 |
Why?
|
| Epithelial Cells | 3 | 2019 | 149 | 0.320 |
Why?
|
| Genome-Wide Association Study | 5 | 2016 | 560 | 0.320 |
Why?
|
| Inflammation | 4 | 2021 | 542 | 0.310 |
Why?
|
| African Americans | 8 | 2019 | 1443 | 0.300 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2019 | 53 | 0.300 |
Why?
|
| Gene Expression | 3 | 2021 | 345 | 0.290 |
Why?
|
| Age of Onset | 4 | 2012 | 100 | 0.290 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 786 | 0.280 |
Why?
|
| Cytokines | 2 | 2020 | 262 | 0.280 |
Why?
|
| Interleukin-5 | 2 | 2020 | 7 | 0.280 |
Why?
|
| Comorbidity | 5 | 2019 | 572 | 0.270 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2019 | 17 | 0.260 |
Why?
|
| Case-Control Studies | 7 | 2019 | 911 | 0.250 |
Why?
|
| Disease Progression | 2 | 2017 | 618 | 0.250 |
Why?
|
| Breath Tests | 6 | 2019 | 21 | 0.240 |
Why?
|
| Respiratory Mucosa | 2 | 2021 | 14 | 0.240 |
Why?
|
| Age Factors | 5 | 2017 | 1204 | 0.240 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 4049 | 0.230 |
Why?
|
| United States | 11 | 2019 | 3983 | 0.220 |
Why?
|
| Scopolamine Derivatives | 2 | 2013 | 9 | 0.210 |
Why?
|
| Sex Factors | 2 | 2018 | 674 | 0.210 |
Why?
|
| Double-Blind Method | 7 | 2019 | 550 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 316 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2019 | 2273 | 0.210 |
Why?
|
| Vital Capacity | 4 | 2020 | 53 | 0.200 |
Why?
|
| Arginine | 2 | 2012 | 18 | 0.190 |
Why?
|
| Drug Resistance | 2 | 2020 | 42 | 0.190 |
Why?
|
| Interleukin-5 Receptor alpha Subunit | 1 | 2020 | 1 | 0.180 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2020 | 25 | 0.180 |
Why?
|
| Interleukin-6 | 2 | 2019 | 248 | 0.180 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2010 | 49 | 0.180 |
Why?
|
| Progesterone Reductase | 1 | 2020 | 3 | 0.180 |
Why?
|
| Steroid Isomerases | 1 | 2020 | 3 | 0.180 |
Why?
|
| Signal Transduction | 3 | 2019 | 701 | 0.180 |
Why?
|
| Leukocytes | 1 | 2020 | 60 | 0.180 |
Why?
|
| Multienzyme Complexes | 1 | 2020 | 17 | 0.180 |
Why?
|
| Triamcinolone | 1 | 2019 | 13 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 171 | 0.170 |
Why?
|
| Influenza Vaccines | 2 | 2010 | 79 | 0.170 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 14 | 0.170 |
Why?
|
| Obesity | 4 | 2021 | 1164 | 0.170 |
Why?
|
| Respiration Disorders | 1 | 2019 | 8 | 0.170 |
Why?
|
| Aging | 2 | 2016 | 953 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 849 | 0.170 |
Why?
|
| Glycoproteins | 1 | 2019 | 46 | 0.170 |
Why?
|
| Phosphoproteins | 1 | 2019 | 55 | 0.160 |
Why?
|
| Influenza, Human | 2 | 2010 | 124 | 0.160 |
Why?
|
| Androstadienes | 2 | 2010 | 21 | 0.160 |
Why?
|
| Perioperative Nursing | 1 | 2018 | 2 | 0.160 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2018 | 29 | 0.160 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 1522 | 0.150 |
Why?
|
| Death | 1 | 2018 | 48 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 213 | 0.150 |
Why?
|
| Tissue and Organ Procurement | 1 | 2018 | 93 | 0.150 |
Why?
|
| Prednisolone | 1 | 2017 | 11 | 0.150 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2016 | 10 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 675 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 53 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 502 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2019 | 1281 | 0.140 |
Why?
|
| Cross-Over Studies | 4 | 2019 | 101 | 0.140 |
Why?
|
| Risk Factors | 5 | 2021 | 3876 | 0.130 |
Why?
|
| Research | 1 | 2015 | 77 | 0.130 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 58 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2012 | 20 | 0.120 |
Why?
|
| Pregnenediones | 1 | 2014 | 2 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 511 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2014 | 23 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 920 | 0.120 |
Why?
|
| Respiratory Mechanics | 1 | 2013 | 7 | 0.120 |
Why?
|
| Bronchial Provocation Tests | 2 | 2011 | 14 | 0.120 |
Why?
|
| Vitamins | 1 | 2014 | 68 | 0.110 |
Why?
|
| Pneumonia | 1 | 2013 | 67 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 93 | 0.110 |
Why?
|
| Skin Tests | 3 | 2010 | 14 | 0.110 |
Why?
|
| Th1 Cells | 1 | 2013 | 29 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 18 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 696 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2013 | 355 | 0.100 |
Why?
|
| Genetic Variation | 3 | 2021 | 247 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 49 | 0.100 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 12 | 0.090 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 41 | 0.090 |
Why?
|
| Acetates | 1 | 2010 | 15 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 110 | 0.090 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2010 | 5 | 0.090 |
Why?
|
| Hispanic Americans | 3 | 2014 | 949 | 0.090 |
Why?
|
| Eosinophilia | 1 | 2010 | 15 | 0.090 |
Why?
|
| Quinolines | 1 | 2010 | 28 | 0.090 |
Why?
|
| Th2 Cells | 1 | 2010 | 15 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2011 | 181 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 12 | 0.090 |
Why?
|
| Linkage Disequilibrium | 4 | 2012 | 192 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2010 | 32 | 0.090 |
Why?
|
| Infant | 1 | 2013 | 1076 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 25 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 38 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2011 | 141 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2011 | 260 | 0.090 |
Why?
|
| Discriminant Analysis | 1 | 2009 | 22 | 0.090 |
Why?
|
| Alleles | 2 | 2020 | 252 | 0.080 |
Why?
|
| Spirometry | 3 | 2019 | 36 | 0.080 |
Why?
|
| Arginase | 1 | 2008 | 9 | 0.080 |
Why?
|
| Vitamin D | 1 | 2010 | 186 | 0.080 |
Why?
|
| Biopsy | 2 | 2020 | 273 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 250 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2021 | 3358 | 0.080 |
Why?
|
| Linear Models | 3 | 2018 | 454 | 0.080 |
Why?
|
| Bronchoconstriction | 1 | 2007 | 3 | 0.080 |
Why?
|
| Airway Resistance | 1 | 2007 | 5 | 0.080 |
Why?
|
| Logistic Models | 3 | 2019 | 788 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 309 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 279 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 26 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2019 | 480 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2017 | 921 | 0.070 |
Why?
|
| Airway Obstruction | 1 | 2006 | 32 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 194 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 161 | 0.060 |
Why?
|
| Prevalence | 2 | 2019 | 986 | 0.060 |
Why?
|
| Genotype | 2 | 2020 | 742 | 0.060 |
Why?
|
| Population Groups | 1 | 2004 | 7 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2004 | 22 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1040 | 0.060 |
Why?
|
| Ethnic Groups | 1 | 2007 | 480 | 0.060 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2015 | 23 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 11 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 149 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2014 | 171 | 0.050 |
Why?
|
| African Continental Ancestry Group | 1 | 2003 | 364 | 0.050 |
Why?
|
| Mice | 1 | 2008 | 2524 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2021 | 68 | 0.050 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2020 | 5 | 0.050 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 143 | 0.050 |
Why?
|
| Haplotypes | 3 | 2006 | 224 | 0.050 |
Why?
|
| Androgens | 1 | 2020 | 34 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2019 | 12 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 301 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 29 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2019 | 47 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 93 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 19 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 58 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2019 | 16 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 62 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 33 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 111 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 258 | 0.040 |
Why?
|
| Puberty | 1 | 2018 | 10 | 0.040 |
Why?
|
| Quality of Life | 2 | 2016 | 915 | 0.040 |
Why?
|
| Family | 1 | 2018 | 115 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 161 | 0.040 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 4 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 15 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2019 | 846 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 197 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2017 | 201 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 16 | 0.030 |
Why?
|
| Bacteria | 1 | 2016 | 50 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 302 | 0.030 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2015 | 3 | 0.030 |
Why?
|
| Pediatrics | 1 | 2018 | 158 | 0.030 |
Why?
|
| Animals | 1 | 2008 | 7694 | 0.030 |
Why?
|
| Education | 1 | 2015 | 38 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 131 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 165 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 463 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 185 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 525 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 185 | 0.030 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2013 | 5 | 0.030 |
Why?
|
| STAT4 Transcription Factor | 1 | 2013 | 17 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2013 | 30 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 436 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 171 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 1133 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2011 | 5 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2011 | 100 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2011 | 7 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 44 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2011 | 17 | 0.020 |
Why?
|
| Exhalation | 1 | 2010 | 5 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 31 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3513 | 0.020 |
Why?
|
| Beclomethasone | 1 | 2010 | 8 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2010 | 15 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 66 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 73 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 465 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 94 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2011 | 92 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 167 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 103 | 0.020 |
Why?
|
| Vaccination | 1 | 2010 | 137 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1523 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 22 | 0.020 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2007 | 3 | 0.020 |
Why?
|
| Methacholine Chloride | 1 | 2007 | 5 | 0.020 |
Why?
|
| London | 1 | 2007 | 3 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2007 | 5 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 90 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 190 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 257 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 36 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 136 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 2181 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 545 | 0.020 |
Why?
|
| Netherlands | 1 | 2003 | 23 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2003 | 13 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 221 | 0.010 |
Why?
|